SEC Form 4 · accession 0000899243-16-020411
Coherus Oncology, Inc. · CHRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter K. Watler
Officer — Chief Technical Officer
Period of report
May 17, 2016
Accepted (ET)
May 19, 2016 · 4:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001512762
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par value | May 17, 2016 | M | 12,000 | $2.0838 | A | 12,000 | I | By Wife |
| Common Stock, $0.0001 par value | May 17, 2016 | S | 12,000 | $20.00 | D | 0 | I | By Wife |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $2.0838 | May 17, 2016 | M | 12,000 | D | — | Feb 27, 2023 | Common Stock | 12,000 | 43,495 | I |
Explanation of responses
- F1The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person's wife.
- F2A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from June 4, 2012, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.